Literature DB >> 31832762

Baseline MRI detected lateral lymph node as a prognostic factor: a cohort study in pN0 low-risk rectal cancer.

Rui-Jia Sun1, Lin Wang2, Xiao-Ting Li1, Qiao-Yuan Lu1, Xiao-Yan Zhang1, Zhen Guan1, Ying-Shi Sun3.   

Abstract

BACKGROUND: It is highly controversial that how to deal with the lateral lymph-node metastasis in patients with rectal cancer. Although lateral lymph node can be detected by preoperative MRI, the metastasis status cannot be accurately determined following standard total mesorectal excision (TME) in low-risk patients. This study was to assess the correlation between preoperative MRI detected lateral lymph-node (LLN) features and prognosis in patients with non-preradiated low recurrence risk rectal cancers.
MATERIALS AND METHODS: This retrospective study included 593 low-risk rectal cancers underwent TME without neoadjuvant chemo-radiotherapy from January 2013 to December 2015. The features of the largest LLN were retrospectively reviewed on preoperative MRI. The relationship of MR-LLN features with overall survival, metastasis-free survival, and local relapse-free survival was analyzed.
RESULTS: A total of 593 patients including 415 cases of pN0, 86 cases of pN1, and 92 cases of pN2 were enrolled in this study. In pN0 patients, at least one visible LLN was detected in 104 patients on primary MRI. The MR-T staging, postoperative therapy status, the presence of MR-LLN, and short axis (SA) of MR-LLN were significantly correlated with the recurrence in pN0 patients (all p < 0.05). The OS and MFS were significantly lower in patients with MR-LLN SA ≥ 8 mm than SA < 8 mm (p < 0.01, HR = 4.35, 95% CI = 1.48-12.77). The OS and MFS of patients with pN0-LLN(+) and SA ≥ 8 mm were similar to pN2-LLN(-) patients. The location of MR-LLN showed no significant impact on prognosis.
CONCLUSION: For low-risk rectal cancers without neoadjuvant chemo-radiotherapy, the presence of MR-LLN is associated with poor prognosis. The pN0-LLN(+) SA ≥ 8 mm patients might be concerned as pN2 patients and receive more intensive neoadjuvant or adjuvant treatment.

Entities:  

Keywords:  Lateral lymph node; Magnetic resonance imaging; Prognosis; Rectal cancer

Year:  2019        PMID: 31832762     DOI: 10.1007/s00432-019-03100-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.

Authors:  Shin Fujita; Takayuki Akasu; Junki Mizusawa; Norio Saito; Yusuke Kinugasa; Yukihide Kanemitsu; Masayuki Ohue; Shoichi Fujii; Manabu Shiozawa; Takashi Yamaguchi; Yoshihiro Moriya
Journal:  Lancet Oncol       Date:  2012-05-15       Impact factor: 41.316

2.  Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Geerard L Beets; Harm J T Rutten; Miranda Kusters
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

Review 3.  Is There Any Reason to Still Consider Lateral Lymph Node Dissection in Rectal Cancer? Rationale and Technique.

Authors:  Miranda Kusters; Keisuke Uehara; Cornelis J H van de Velde; Yoshihiro Moriya
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

4.  Chemical shift effect predicting lymph node status in rectal cancer using high-resolution MR imaging with node-for-node matched histopathological validation.

Authors:  Hongmei Zhang; Chongda Zhang; Zhaoxu Zheng; Feng Ye; Yuan Liu; Shuangmei Zou; Chunwu Zhou
Journal:  Eur Radiol       Date:  2017-02-06       Impact factor: 5.315

5.  Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease?

Authors:  Takashi Akiyoshi; Toshiaki Watanabe; Satoshi Miyata; Kenjiro Kotake; Tetsuichiro Muto; Kenichi Sugihara
Journal:  Ann Surg       Date:  2012-06       Impact factor: 12.969

6.  Applicability of American Joint Committee on Cancer and College of American Pathologists Regression Grading System in Rectal Cancer.

Authors:  Tarkan Jäger; Daniel Neureiter; Romana Urbas; Eckhard Klieser; Wolfgang Hitzl; Klaus Emmanuel; Adam Dinnewitzer
Journal:  Dis Colon Rectum       Date:  2017-08       Impact factor: 4.585

7.  Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.

Authors:  Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan Moran; Lennart Blomqvist; Ian Swift; David J Sebag-Montefiore; Paris Tekkis; Gina Brown
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

8.  Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison.

Authors:  Gina Brown; Catherine J Richards; Michael W Bourne; Robert G Newcombe; Andrew G Radcliffe; Nicholas S Dallimore; Geraint T Williams
Journal:  Radiology       Date:  2003-05       Impact factor: 11.105

9.  High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size?

Authors:  Joo Hee Kim; Geerard L Beets; Myeong-Jin Kim; Alfons G H Kessels; Regina G H Beets-Tan
Journal:  Eur J Radiol       Date:  2004-10       Impact factor: 3.528

Review 10.  Training and quality assurance for rectal cancer: 20 years of data is enough.

Authors:  Phil Quirke
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.